573 related articles for article (PubMed ID: 33788177)
41. Biologics for Psoriasis.
Wride AM; Chen GF; Spaulding SL; Tkachenko E; Cohen JM
Dermatol Clin; 2024 Jul; 42(3):339-355. PubMed ID: 38796266
[TBL] [Abstract][Full Text] [Related]
42. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
[TBL] [Abstract][Full Text] [Related]
43. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
44. Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of pasi score.
Husein-ElAhmed H; Husein-ElAhmed S
Clin Exp Dermatol; 2024 Apr; ():. PubMed ID: 38618735
[TBL] [Abstract][Full Text] [Related]
45. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment.
Mastorino L; Dapavo P; Susca S; Cariti C; Siliquini N; Verrone A; Stroppiana E; Ortoncelli M; Quaglino P; Ribero S
J Dtsch Dermatol Ges; 2024 Jan; 22(1):34-42. PubMed ID: 37926830
[TBL] [Abstract][Full Text] [Related]
46. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
47. Biologics for severe, chronic plaque psoriasis: An Australian cost-utility analysis.
Sun HY; Keller E; Suresh H; Sebaratnam DF
JAAD Int; 2021 Dec; 5():1-8. PubMed ID: 34816130
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points.
Puig L; López A; Vilarrasa E; García I
J Eur Acad Dermatol Venereol; 2014 Dec; 28(12):1633-53. PubMed ID: 24033851
[TBL] [Abstract][Full Text] [Related]
49. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
Armstrong AW; Betts KA; Signorovitch JE; Sundaram M; Li J; Ganguli AX; Wu EQ
Curr Med Res Opin; 2018 Jul; 34(7):1325-1333. PubMed ID: 29619856
[TBL] [Abstract][Full Text] [Related]
50. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
51. Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
Huang IH; Yu CL; Tai CC; Tu YK; Chi CC
J Dtsch Dermatol Ges; 2022 Sep; 20(9):1201-1209. PubMed ID: 36028470
[TBL] [Abstract][Full Text] [Related]
52. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
53. An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan.
Saeki H; Ishii K; Joshi A; Bensimon AG; Yang H; Kawaguchi I
J Dermatolog Treat; 2022 Feb; 33(1):229-239. PubMed ID: 32178555
[TBL] [Abstract][Full Text] [Related]
54. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
Papp KA; Gordon KB; Langley RG; Lebwohl MG; Gottlieb AB; Rastogi S; Pillai R; Israel RJ
Br J Dermatol; 2018 Aug; 179(2):320-328. PubMed ID: 29488226
[TBL] [Abstract][Full Text] [Related]
55. Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials.
Chiu HY; Hung YT; Huang YH
Ther Adv Chronic Dis; 2023; 14():20406223231206225. PubMed ID: 37901688
[TBL] [Abstract][Full Text] [Related]
56. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
Mrowietz U; Warren RB; Leonardi CL; Saure D; Petto H; Hartz S; Dossenbach M; Reich K
J Eur Acad Dermatol Venereol; 2021 May; 35(5):1161-1175. PubMed ID: 33480102
[TBL] [Abstract][Full Text] [Related]
57. Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.
Shear NH; Betts KA; Soliman AM; Joshi A; Wang Y; Zhao J; Gisondi P; Sinvhal R; Armstrong AW
J Am Acad Dermatol; 2021 Sep; 85(3):572-581. PubMed ID: 33631216
[TBL] [Abstract][Full Text] [Related]
58. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans.
Feldman SR; Wu JJ; Rastogi S; Menges B; Lingohr-Smith M; Lin J
J Med Econ; 2018 May; 21(5):537-541. PubMed ID: 29357713
[TBL] [Abstract][Full Text] [Related]
59. Onset of Action of Biologics in Patients With Moderate-to-Severe Psoriasis.
Papp KA; Lebwohl MG
J Drugs Dermatol; 2018 Mar; 17(3):247-250. PubMed ID: 29537442
[TBL] [Abstract][Full Text] [Related]
60. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
